Effect of Ultralow Doses of Antibodies to S-100 Protein in Animals with Impaired Cognitive Function and Disturbed Emotional and Neurological Status under Conditions of Experimental Alzheimer Disease

• Published in: Bulletin of experimental biology and medicine Vol. 148; no. 3; pp. 533 - 535
• Main Authors: Voronina, T. A, Belopol'skaya, M. V, Kheyfets, I. A, Dugina, Yu. L, Sergeeva, S. A, Epshtein, O. I
• Format: Journal Article
• Language: English; Russian
• Published: Boston Boston : Springer US 01.09.2009; Springer US; Springer Nature B.V
• Subjects: Alzheimer disease; Alzheimer Disease - drug therapy; Alzheimer Disease - pathology; Animals; Antibodies - immunology; Antibodies - therapeutic use; Anxiety - drug therapy; Avoidance Learning - drug effects; Biomedical and Life Sciences; Biomedicine; Cell Biology; Cognition - drug effects; Cognition Disorders - drug therapy; Internal Medicine; Laboratory Medicine; Male; Neuropsychological Tests; Pathology; Rats; S-100 protein; S100 Proteins - immunology; scopolamine; Scopolamine - therapeutic use; ultralow doses; ultralow doses; S-100 protein; Alzheimer disease; scopolamine
• ISSN: 0007-4888; 1573-8221
• DOI: 10.1007/s10517-010-0757-y

Course administration of ultralow doses of antibodies to S-100 protein restores cognitive functions and neurological status, improves emotional state, and reduces anxiety in animals with modeled Alzheimer disease based on cholinergic system defi ciency caused by subchronic treatment with scopolamine.